Marketing and distribution would not be a big issue as there is only a small addressable population and really not many if any competing products. If we can duplicate the same result from the previous trial and approve for sale I think we will have patients lining up for ANP drug.
If a small Aussie biotech can develop and commercialized drug that outperform drugs from multi billion US pharma which we will, marketing and distribution to 10K-15K patients should be a breeze and least of our worry.
I am dreaming here but can ANP be the next CSL, Cochlear or Promedicus? Only time will tell.
Marketing and distribution would not be a big issue as there is...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.8¢ |
Change
0.004(6.25%) |
Mkt cap ! $61.30M | |||
| Open | High | Low | Value | Volume |
| 6.6¢ | 7.1¢ | 6.5¢ | $198.2K | 2.885M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 14845 | 6.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
6.8¢ |
Change
0.004 ( 14.3 %) |
||||
| Open | High | Low | Volume | ||
| 6.6¢ | 7.1¢ | 6.6¢ | 295714 | ||
| Last updated 15.58pm 26/04/2024 ? | |||||
| PER (ASX) Chart |